sellWeak cluster of 310b5-1 plan
Henry E. Pelish sold $16k of NUVL
Chief Scientific Officer at Nuvalent, Inc.. 200 shares at an average of $79.82, traded Jun 6, 2025, filed Jun 10, 2025.
Warning score
0Value
$16k
200 shares
Holdings after
63,101
-0% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- 0Trade size$16k at market
- 0Share of holdings soldSold 0.3% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-25-084388, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 6, 2025 | MOption exercise Class A Common Stock10b5-1 | +100 | $27.85 | $2,785 | 63,201 | Jun 10, 2025 |
| Jun 6, 2025 | MOption exercise Class A Common Stock10b5-1 | +100 | $29.33 | $2,933 | 63,301 | Jun 10, 2025 |
| Jun 6, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -200 | $79.82 | $16k | 63,101 | Jun 10, 2025 |
| Jun 6, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -100 | $0.00 | $0 | 32,352 | Jun 10, 2025 |
| Jun 6, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -100 | $0.00 | $0 | 32,075 | Jun 10, 2025 |
Related signals
Other insiders at Nuvalent, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 17Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $1.1M 11,430 shares | -12% | |
| 17Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $1.1M 11,430 shares | -12% | |
| 25Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $1.2M 11,430 shares | -12% | |
| 14Weak | Nuvalent, Inc. | Deborah Ann Miller Chief Legal Officer | $543k 5,500 shares | -8% | |
| 32Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $2.5M 25,130 shares | -23% | |
| 30Weak | Nuvalent, Inc. | Henry E. Pelish Chief Scientific Officer | $3.4M 35,104 shares | -35% | |
| 30Weak | Nuvalent, Inc. | James Richard Porter President and CEO | $3.0M 30,000 shares | -8% | |
| 14Weak | Nuvalent, Inc. | Deborah Ann Miller Chief Legal Officer | $567k 5,500 shares | -8% | |
| 14Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $567k 5,500 shares | -9% | |
| 7Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $561k 5,500 shares | -9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.